MBX Stock Overview
A life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Microbix Biosystems Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.49 |
| 52 Week High | CA$0.52 |
| 52 Week Low | CA$0.29 |
| Beta | 0.21 |
| 1 Month Change | 19.51% |
| 3 Month Change | 53.13% |
| 1 Year Change | 25.64% |
| 3 Year Change | -20.97% |
| 5 Year Change | 104.17% |
| Change since IPO | -18.33% |
Recent News & Updates
Recent updates
Microbix Biosystems Inc. (TSE:MBX) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 04
Microbix Biosystems' (TSE:MBX) Shareholders Should Assess Earnings With Caution
Aug 22Why Microbix Biosystems' (TSE:MBX) Earnings Are Weaker Than They Seem
Feb 21Microbix Biosystems Inc. (TSE:MBX) Just Reported Earnings, And Analysts Cut Their Target Price
Feb 17Microbix Biosystems Inc.'s (TSE:MBX) Shares Climb 29% But Its Business Is Yet to Catch Up
Dec 23Is Microbix Biosystems (TSE:MBX) Using Debt Sensibly?
Nov 03Is Microbix Biosystems (TSE:MBX) Using Debt In A Risky Way?
Jul 22Some Shareholders Feeling Restless Over Microbix Biosystems Inc.'s (TSE:MBX) P/S Ratio
May 17Time To Worry? Analysts Are Downgrading Their Microbix Biosystems Inc. (TSE:MBX) Outlook
Dec 27Microbix Biosystems (TSE:MBX) Has A Pretty Healthy Balance Sheet
Aug 08Microbix Biosystems' (TSE:MBX) Solid Profits Have Weak Fundamentals
May 20Microbix Biosystems (TSE:MBX) Seems To Use Debt Quite Sensibly
Feb 06One Microbix Biosystems Inc. (TSE:MBX) Analyst Just Made A Major Cut To Next Year's Estimates
Dec 28Is Microbix Biosystems (TSE:MBX) A Risky Investment?
Oct 14Microbix Biosystems Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 15A Look At The Fair Value Of Microbix Biosystems Inc. (TSE:MBX)
May 17Most Shareholders Will Probably Find That The CEO Compensation For Microbix Biosystems Inc. (TSE:MBX) Is Reasonable
Mar 24We Think Microbix Biosystems (TSE:MBX) Has A Fair Chunk Of Debt
Jan 29
Shareholder Returns
| MBX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 1.0% | -1.8% | 0.6% |
| 1Y | 25.6% | 10.4% | 17.9% |
Return vs Industry: MBX exceeded the Canadian Biotechs industry which returned 10.4% over the past year.
Return vs Market: MBX exceeded the Canadian Market which returned 17.9% over the past year.
Price Volatility
| MBX volatility | |
|---|---|
| MBX Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 12.5% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CA Market | 18.5% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: MBX has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: MBX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | n/a | Cameron Groome | www.microbix.com |
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services.
Microbix Biosystems Inc. Fundamentals Summary
| MBX fundamental statistics | |
|---|---|
| Market cap | CA$63.73m |
| Earnings (TTM) | CA$3.52m |
| Revenue (TTM) | CA$25.39m |
18.9x
P/E Ratio2.6x
P/S RatioIs MBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBX income statement (TTM) | |
|---|---|
| Revenue | CA$25.39m |
| Cost of Revenue | CA$10.00m |
| Gross Profit | CA$15.39m |
| Other Expenses | CA$11.87m |
| Earnings | CA$3.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.026 |
| Gross Margin | 60.61% |
| Net Profit Margin | 13.86% |
| Debt/Equity Ratio | 20.1% |
How did MBX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 00:03 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Microbix Biosystems Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Neil Linsdell | iA Capital Markets |